The Ups And Downs In Drug Design
Download The Ups And Downs In Drug Design full books in PDF, epub, and Kindle. Read online free The Ups And Downs In Drug Design ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : Victor E. Marquez |
| Publisher | : CRC Press |
| Total Pages | : 566 |
| Release | : 2021-11-15 |
| Genre | : Medical |
| ISBN | : 1000462943 |
The Ups and Downs in Drug Design: Adventures in Medicinal Chemistry highlights the necessity for an integrative approach in medicinal chemistry and chemical biology. As medicinal chemistry is not a monolithic science, it is important to emphasize the other various disciplines that are required for successful drug design. This book presents the author’s own personal experience in this field and describes the "ups" and "downs" that come with drug discovery. It is an excellent companion text for graduate and postgraduate students who would like further insight into the parameters of drug design, including the challenges that come with the project. Key Features Illustrates "real-life" examples in medicinal chemistry Integrates the use of physical, chemical, and biological concepts that are important in drug design Highlights the "ups" and "downs" that come with drug discovery Aims to inspire students who may be struggling with the challenges and thought process in drug design Intends to be an excellent companion text for graduate and postgraduate students
| Author | : VICTOR. MARQUEZ |
| Publisher | : CRC Press |
| Total Pages | : 464 |
| Release | : 2021-11-02 |
| Genre | : |
| ISBN | : 9781032067100 |
The Ups and Downs in Drug Design: Adventures in Medicinal Chemistry highlights the necessity for an integrative approach in Medicinal Chemistry and Chemical Biology. As Medicinal Chemistry is not a monolithic science, it is important to emphasize the other various disciplines that are required for successful drug design. This book presents the authors' own personal experience in this field and describes the "ups" and "downs" that come with drug discovery. This book is an excellent companion text for graduate and postgraduate students who would like further insight into the parameters of drug design, including the challenges that come with the project. Key Features: Describes 'real life' examples in Medicinal Chemistry. Integrates the use of physical, chemical, and biological concepts that are important in drug design. Highlights the "ups" and "downs" that come with drug discovery. Aims to inspire students who may be struggling with the challenges and thought process in drug design. Intends to be an excellent companion text, illustrating real life experiences, for graduate and postgraduate students.
| Author | : Tamas Bartfai |
| Publisher | : Academic Press |
| Total Pages | : 377 |
| Release | : 2013-05-18 |
| Genre | : Medical |
| ISBN | : 0124095194 |
The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer's disease, untreatable pain, antibiotics and more. This book carefully exposes the gap between the medicines and therapies we need and the current business path. By analyzing the situation and discussing prospects for the next decade, the The Future of Drug Discovery is a timely book for all those who care about the development needs for drugs for disease. - Provides an in-depth, broad perspective on the crisis in drug industry - Exposes the disconnect between what society needs and what the drug companies are working on - Analyses and projects over 10 years into the future - Explains what it means for scientists and society - Determines what is needed to be done to make sure that the industry responds to society's needs, remains commercially attractive and answers the question as to who decides which diseases to treat
| Author | : Eric B. Holmgren |
| Publisher | : CRC Press |
| Total Pages | : 252 |
| Release | : 2013-10-24 |
| Genre | : Mathematics |
| ISBN | : 1466507470 |
Theory of Drug Development presents a formal quantitative framework for understanding drug development that goes beyond simply describing the properties of the statistics in individual studies. It examines the drug development process from the perspectives of drug companies and regulatory agencies. By quantifying various ideas underlying drug development, the book shows how to systematically address problems, such as: Sizing a phase 2 trial and choosing the range of p-values that will trigger a follow-up phase 3 trial Deciding whether a drug should receive marketing approval based on its phase 2/3 development program and recent experience with other drugs in the same clinical area Determining the impact of adaptive designs on the quality of drugs that receive marketing approval Designing a phase 3 pivotal study that permits the data-driven adjustment of the treatment effect estimate Knowing when enough information has been gathered to show that a drug improves the survival time for the whole patient population Drawing on his extensive work as a statistician in the pharmaceutical industry, the author focuses on the efficient development of drugs and the quantification of evidence in drug development. He provides a rationale for underpowered phase 2 trials based on the notion of efficiency, which leads to the identification of an admissible family of phase 2 designs. He also develops a framework for evaluating the strength of evidence generated by clinical trials. This approach is based on the ratio of power to type 1 error and transcends typical Bayesian and frequentist statistical analyses.
| Author | : Alex Avdeef |
| Publisher | : John Wiley & Sons |
| Total Pages | : 741 |
| Release | : 2012-04-11 |
| Genre | : Medical |
| ISBN | : 1118286030 |
Explains how to perform and analyze the results of the latest physicochemical methods With this book as their guide, readers have access to all the current information needed to thoroughly investigate and accurately determine a compound's pharmaceutical properties and their effects on drug absorption. The book emphasizes oral absorption, explaining all the physicochemical methods used today to analyze drug candidates. Moreover, the author provides expert guidance to help readers analyze the results of their studies in order to select the most promising drug candidates. This Second Edition has been thoroughly updated and revised, incorporating all the latest research findings, methods, and resources, including: Descriptions and applications of new PAMPA models, drawing on more than thirty papers published by the author's research group Two new chapters examining permeability and Caco-2/MDCK and permeability and the blood-brain barrier Expanded information and methods to support pKa determination New examples explaining the treatment of practically insoluble test compounds Additional case studies demonstrating the use of the latest physicochemical techniques New, revised, and expanded database tables throughout the book Well over 200 drawings help readers better understand difficult concepts and provide a visual guide to complex procedures. In addition, over 800 references serve as a gateway to the primary literature in the field, facilitating further research into all the topics covered in the book. This Second Edition is recommended as a reference for researchers in pharmaceutical R&D as well as in agrochemical, environmental, and other related areas of research. It is also recommended as a supplemental text for graduate courses in pharmaceutics.
| Author | : Victor Roy |
| Publisher | : Univ of California Press |
| Total Pages | : 216 |
| Release | : 2023-01-24 |
| Genre | : Medical |
| ISBN | : 0520388720 |
A free open access ebook is available upon publication. Learn more at www.luminosoa.org. Capitalizing a Cure takes readers into the struggle over a medical breakthrough to investigate the power of finance over business, biomedicine, and public health. When curative treatments for hepatitis C launched in 2013, sticker shock over their prices intensified the global debate over access to new medicines. Weaving historical research with insights from political economy and science and technology studies, Victor Roy demystifies an oft-missed dynamic in this debate: the reach of financialized capitalism into how medicines are made, priced, and valued. Roy’s account moves between public and private labs, Wall Street and corporate board rooms, and public health meetings and health centers to trace the ways in which curative medicines became financial assets dominated by strategies of speculation and extraction at the expense of access and care. Provocative and sobering, this book illuminates the harmful impact of allowing financial markets to determine who heals and who suffers and points to the necessary work of building more equitable futures.
| Author | : Toby Freedman |
| Publisher | : CSHL Press |
| Total Pages | : 408 |
| Release | : 2008 |
| Genre | : Biotechnology |
| ISBN | : 0879697253 |
An essential guide for students in the life sciences, established researchers, and career counselors, this resource features discussions of job security, future trends, and potential career paths. Even those already working in the industry will find helpful information on how to take advantage of opportunities within their own companies and elsewhere.
| Author | : Susan Miller |
| Publisher | : Woodhead Publishing |
| Total Pages | : 538 |
| Release | : 2016-11-08 |
| Genre | : Medical |
| ISBN | : 0081006322 |
Managing the Drug Discovery Process: How to Make It More Efficient and Cost-Effective thoroughly examines the current state of pharmaceutical research and development by providing chemistry-based perspectives on biomedical research, drug hunting and innovation. The book also considers the interplay of stakeholders, consumers, and the drug firm with attendant factors, including those that are technical, legal, economic, demographic, political, social, ecological, and infrastructural. Since drug research can be a high-risk, high-payoff industry, it is important to researchers to effectively and strategically manage the drug discovery process. This book takes a closer look at increasing pre-approval costs for new drugs and examines not only why these increases occur, but also how they can be overcome to ensure a robust pharmacoeconomic future. Written in an engaging manner and including memorable insights, this book is aimed at redirecting the drug discovery process to make it more efficient and cost-effective in order to achieve the goal of saving countless more lives through science. A valuable and compelling resource, this is a must-read for all students and researchers in academia and the pharmaceutical industry. - Considers drug discovery in multiple R&D venues, including big pharma, large biotech, start-up ventures, academia, and nonprofit research institutes - Analyzes the organization of pharmaceutical R&D, taking into account human resources considerations like recruitment and configuration, management of discovery and development processes, and the coordination of internal research within, and beyond, the organization, including outsourced work - Presents a consistent, well-connected, and logical dialogue that readers will find both comprehensive and approachable
| Author | : Frederick A. Valeriote |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 413 |
| Release | : 2012-12-06 |
| Genre | : Medical |
| ISBN | : 1461534925 |
The focus of the 22nd Annual Detroit Cancer Symposium was the presentation and discussion of cytotoxic agents, with a significant portion of the symposium including the exciting frontiers of drug discovery being explored by the National Cooperative Drug Discovery Groups (NCDDG) Program. The symposium brought together a large number of investigators from government, universities and pharmaceutical companies involved in the discovery and development of new anticancer agents. Exciting new leads were presented and the status of others presently under development was discussed. Of particular significance has been the initiation of renewed efforts in the area of natural product drug discovery, where the discovery of new cytotoxics is very promising at the moment. A number of major changes have occurred during the last decade in research on drug discovery of cytotoxic agents. Critical reviews of a number of the models and concepts underlying drug discovery represented a continuous thread throughout the meeting, being constantly discussed in terms of their advantages, disadvantages and capabilities of discovering solid tumor active anticancer agents. A recent development which is to be much applauded and which portends to great discoveries is the new relationship formed between Government, University of Industry. The NCDDG mechanism which stimulates this interaction is an inexpensive manner to greatly magnify the drug discovery and development effort nationally. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development represents a forum which will become the major mode for bringing together these three different components in the equation to regularly discuss new results and ideas.
| Author | : Adeboye Adejare |
| Publisher | : Academic Press |
| Total Pages | : 310 |
| Release | : 2016-09-20 |
| Genre | : Medical |
| ISBN | : 0128028114 |
Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease examines the drug discovery process for neurodegenerative diseases by focusing specifically on Alzheimer's Disease and illustrating the paradigm necessary to ensure future research and treatment success. The book explores diagnosis, epidemiology, drug discovery strategies, current therapeutics, and much more to provide a holistic approach to the discovery, development, and treatment of Alzheimer's Disease. Through its coverage of the latest research in targeted drug design, preclinical studies, and mouse and rat models, the book is a must-have resource for all pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers working in this area. It illustrates why these drugs tend to fail at the clinical stage, and examines Alzheimer's Disease within the overall context of improving the drug discovery process for the treatment of other neurodegenerative disorders. - Provides a compilation of chemical considerations required in drug discovery for the treatment of neurodegenerative disorders - Examines different classes of compounds currently being used in discovery and development stages - Explores in vitro and in vivo models with respect to their ability to translate these models to human conditions - Distills the most significant information across multiple areas of Alzheimer's disease research to provide a single, comprehensive, and balanced resource
